Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy.

导出 OA

翻译打印收藏纠错

作者： Jennifer S,Gewandter ^[1] ; Laurie,Burke ^[2] ; Guido,Cavaletti ^[3] ; Robert H,Dworkin ^[1] ; Christopher,Gibbons ^[4] ; Tony D,Gover ^[5] ; David N,Herrmann ^[1] ; Justin C,Mcarthur ^[6] ; Michael P,McDermott ^[1] ; Bob A,Rappaport ^[7] ; Bryce B,Reeve ^[8] ; James W,Russell ^[9] ; A Gordon,Smith ^[10] ; Shannon M,Smith ^[1] ; Dennis C,Turk ^[11] ; Aaron I,Vinik ^[12] ; Roy,Freeman ^[4]

作者单位： University of Rochester, Rochester, New York, USA. ^[1] LORA Group, LLC, Royal Oak, Maryland, USA. ^[2] University of Milano-Bicocca, Monza, Italy. ^[3] Harvard Medical School, Boston, Massachusetts, USA. ^[4] U.S. Army Medical Research and Materiel Command, Fort Detrick, Maryland, USA. ^[5] Johns Hopkins University, Baltimore, Maryland, USA. ^[6] Arlington, Virginia, USA. ^[7] University of North Carolina, Chapel Hill, North Carolina, USA. ^[8] University of Maryland and Veterans Administration Maryland Health Care System, Baltimore, Maryland, USA. ^[9] University of Utah, Salt Lake City, Utah, USA. ^[10] University of Washington, Seattle, Washington, USA. ^[11] Eastern Virginia Medical School, Norfolk, Virginia, USA. ^[12]

关键词 content validity drug development measure development outcome measures peripheral neuropathy systematic review

主题词糖尿病神经病变(Diabetic Neuropathies);HIV感染(HIV Infections);人类(Humans);周围神经系统疾病(Peripheral Nervous System Diseases)

DOI 10.1002/mus.25264

PMID 27447116

发布时间 2024-06-03

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交